Home › Funds › Evergreen Quality Fund GP, Ltd. › FDMT
Evergreen Quality Fund GP, Ltd. position in FDMT
4D MOLECULAR THERAPEUTICS IN · Health Care
Evergreen Quality Fund GP, Ltd. reported holding 951,474 shares of FDMT (4D MOLECULAR THERAPEUTICS IN) in its Q2 2026 13F filing — a position valued at US$12.7M, representing 0.20% of its reported portfolio and ranking #31 among its reported holdings. Evergreen Quality Fund GP, Ltd. has disclosed FDMT holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Evergreen Quality Fund GP, Ltd.'s FDMT position evolved
Evergreen Quality Fund GP, Ltd. first disclosed a stake in FDMT in Q4 2025 at 951,474 shares (US$7.1M). The position peaked in Q2 2026 at 951,474 shares, worth US$12.7M. Across 3 filings, Evergreen Quality Fund GP, Ltd. held the position steady without any share-count change. The most recent filing (Q2 2026) shows 951,474 shares valued at US$12.7M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 951.47K | $7.14M | New |
| Q1 2026 | 951.47K | $8.86M | Hold |
| Q2 2026 | 951.47K | $12.65M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About FDMT and 13F data
FDMT (4D MOLECULAR THERAPEUTICS IN) is a Health Care company. 35 other funds we track also report a position in FDMT — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$67.2M), Novo Holdings A/S (US$43.2M), BVF INC/IL (US$38.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding FDMT
- RA CAPITAL MANAGEMENT, L.P. 5.05M sh · $67.16M · Q2 2026
- Novo Holdings A/S 3.25M sh · $43.21M · Q2 2026
- BVF INC/IL 2.88M sh · $38.29M · Q2 2026
- Trails Edge Capital Partners, LP 2.23M sh · $29.63M · Q2 2026
- ARMISTICE CAPITAL, LLC 2.00M sh · $26.60M · Q2 2026
- Parkman Healthcare Partners LLC 948.18K sh · $12.61M · Q2 2026
- DIADEMA PARTNERS LP 571.11K sh · $7.60M · Q2 2026
- ACUTA CAPITAL PARTNERS, LLC 507.80K sh · $6.75M · Q2 2026
- Catalio Capital Management, LP 471.25K sh · $6.27M · Q2 2026
- Opaleye Management Inc. 334.44K sh · $4.45M · Q2 2026
More on Evergreen Quality Fund GP, Ltd.
FAQ
How long has Evergreen Quality Fund GP, Ltd. held FDMT?
Evergreen Quality Fund GP, Ltd. has disclosed FDMT holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Evergreen Quality Fund GP, Ltd.'s current position in FDMT?
As of Q2 2026, Evergreen Quality Fund GP, Ltd. holds 951.47K shares of FDMT (4D MOLECULAR THERAPEUTICS IN), valued at $12.65M, representing 0.20% of its reported portfolio and ranking #31.
Has Evergreen Quality Fund GP, Ltd. been buying or selling FDMT?
In the latest 13F filing (Q2 2026), Evergreen Quality Fund GP, Ltd. held unchanged its position in FDMT. The position peaked in Q2 2026 at 951.47K shares.
Which other funds hold FDMT?
Other major institutional holders of FDMT include RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, BVF INC/IL, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.